Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology

Joseph M. Sanfrancesco, Liang Cheng

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The topic of tumoral heterogeneity at the genetic level has become relevant in various solid origin tumors, particularly in an age of targeted treatment. Renal cell carcinoma is known for a sizable subset of tumors presenting at advanced clinical stage, further highlighting the importance and timeliness of this topic and its potential impact on adjuvant therapy. Recent studies have shown that molecular aberrations in renal cell carcinoma go beyond known truncal mutations and that downstream, subclonal aberrations are spatially heterogenous. Intratumoral heterogeneity as well as the differences in the molecular landscape between primary and metastatic lesions remains underappreciated, often due to inadequate sampling of tumors. The overall effect of these factors on the efficacy of current treatment options in renal cell carcinoma remains unknown; however, several recent studies have attempted to elucidate the extent and impact genetic heterogeneity in renal cell neoplasia may have on patient treatment and prognosis.

Original languageEnglish (US)
Pages (from-to)23-28
Number of pages6
JournalCritical Reviews in Oncology/Hematology
Volume119
DOIs
StatePublished - Nov 1 2017

Fingerprint

Renal Cell Carcinoma
Genetic Heterogeneity
Neoplasms
Therapeutics
Kidney
Mutation

Keywords

  • Clonal evolution
  • Kidney
  • Precision immuno-oncology
  • Renal cell carcinoma
  • Targeted therapy
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Complexity of the genomic landscape of renal cell carcinoma : Implications for targeted therapy and precision immuno-oncology. / Sanfrancesco, Joseph M.; Cheng, Liang.

In: Critical Reviews in Oncology/Hematology, Vol. 119, 01.11.2017, p. 23-28.

Research output: Contribution to journalReview article

@article{0b1b641b176f4af19d006cc6c6cc41f1,
title = "Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology",
abstract = "The topic of tumoral heterogeneity at the genetic level has become relevant in various solid origin tumors, particularly in an age of targeted treatment. Renal cell carcinoma is known for a sizable subset of tumors presenting at advanced clinical stage, further highlighting the importance and timeliness of this topic and its potential impact on adjuvant therapy. Recent studies have shown that molecular aberrations in renal cell carcinoma go beyond known truncal mutations and that downstream, subclonal aberrations are spatially heterogenous. Intratumoral heterogeneity as well as the differences in the molecular landscape between primary and metastatic lesions remains underappreciated, often due to inadequate sampling of tumors. The overall effect of these factors on the efficacy of current treatment options in renal cell carcinoma remains unknown; however, several recent studies have attempted to elucidate the extent and impact genetic heterogeneity in renal cell neoplasia may have on patient treatment and prognosis.",
keywords = "Clonal evolution, Kidney, Precision immuno-oncology, Renal cell carcinoma, Targeted therapy, Tumor heterogeneity",
author = "Sanfrancesco, {Joseph M.} and Liang Cheng",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.critrevonc.2017.09.011",
language = "English (US)",
volume = "119",
pages = "23--28",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Complexity of the genomic landscape of renal cell carcinoma

T2 - Implications for targeted therapy and precision immuno-oncology

AU - Sanfrancesco, Joseph M.

AU - Cheng, Liang

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The topic of tumoral heterogeneity at the genetic level has become relevant in various solid origin tumors, particularly in an age of targeted treatment. Renal cell carcinoma is known for a sizable subset of tumors presenting at advanced clinical stage, further highlighting the importance and timeliness of this topic and its potential impact on adjuvant therapy. Recent studies have shown that molecular aberrations in renal cell carcinoma go beyond known truncal mutations and that downstream, subclonal aberrations are spatially heterogenous. Intratumoral heterogeneity as well as the differences in the molecular landscape between primary and metastatic lesions remains underappreciated, often due to inadequate sampling of tumors. The overall effect of these factors on the efficacy of current treatment options in renal cell carcinoma remains unknown; however, several recent studies have attempted to elucidate the extent and impact genetic heterogeneity in renal cell neoplasia may have on patient treatment and prognosis.

AB - The topic of tumoral heterogeneity at the genetic level has become relevant in various solid origin tumors, particularly in an age of targeted treatment. Renal cell carcinoma is known for a sizable subset of tumors presenting at advanced clinical stage, further highlighting the importance and timeliness of this topic and its potential impact on adjuvant therapy. Recent studies have shown that molecular aberrations in renal cell carcinoma go beyond known truncal mutations and that downstream, subclonal aberrations are spatially heterogenous. Intratumoral heterogeneity as well as the differences in the molecular landscape between primary and metastatic lesions remains underappreciated, often due to inadequate sampling of tumors. The overall effect of these factors on the efficacy of current treatment options in renal cell carcinoma remains unknown; however, several recent studies have attempted to elucidate the extent and impact genetic heterogeneity in renal cell neoplasia may have on patient treatment and prognosis.

KW - Clonal evolution

KW - Kidney

KW - Precision immuno-oncology

KW - Renal cell carcinoma

KW - Targeted therapy

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85031999365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031999365&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.09.011

DO - 10.1016/j.critrevonc.2017.09.011

M3 - Review article

C2 - 29065981

AN - SCOPUS:85031999365

VL - 119

SP - 23

EP - 28

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -